Viewing StudyNCT05155709

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 4:58 PM
Last Modification Date: 2024-10-26 @ 2:20 PM
Study NCT ID: NCT05155709
Status: COMPLETED
Last Update Posted: 2024-07-05
First Post: 2021-10-20
Brief Title: A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia AML Who Are Ineligible for Chemotherapy
Sponsor: Novartis Pharmaceuticals
Organization: Novartis
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Acute Myeloid Leukemia
Keywords:
Name View
presenting with high-risk clinical features View
Acute myeloid leukemia View
AML View
Azacitidine View
venetoclax View
p53 View
MDM2 View
siremadlin View
HDM201 View
unfit adult AML participants View
newly diagnosed unfit AML View